EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients

Rhea Suribhatla iD, Thomas Starkey iD, Maria C Ionescu, Antonio Pagliuca iD, Alex Richter iD, Lennard Y W Lee iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18782 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Rhea Suribhatla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Medical School, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunocompromised patients, such as those with a haematological malignancy, are at higher risk of SARS‐CoV‐2 infection, severe outcomes and mortality. Tixagevimab/cilgavimab is a monoclonal antibody combination which binds to the SARS‐CoV‐2 spike protein. The PROVENT phase III clinical trial reported that tixagevimab/cilgavimab prophylaxis significantly reduced the risk of COVID‐19 infection in immunocompromised participants. However, the trial was conducted before the Omicron variant became prevalent. This systematic review and meta‐analysis provide an up‐to‐date summary of the real‐world effectiveness of tixagevimab/cilgavimab in immunocompromised patients, including patients with haematological malignancies. Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID‐19 infections after tixagevimab/cilgavimab, were included. COVID‐19‐related hospitalisations, intensive care admissions and mortality were also assessed. A meta‐analysis was performed to ascertain overall clinical effectiveness. Eighteen studies, with 25 345 immunocompromised participants, including 5438 patients with haematological pathologies, were included in the review. The overall clinical effectiveness of tixagevimab/cilgavimab against COVID‐19 breakthrough infection, hospitalisation, intensive care admission and COVID‐19‐specific mortality was 40.54%, 66.19%, 82.13% and 92.39%, respectively. This review highlights the clinical effectiveness of tixagevimab/cilgavimab at reducing COVID‐19 infection and severe outcomes for immunosuppressed individuals, including patients with a haematological malignancy, during the Omicron‐predominant era. Real‐world studies are important to provide ongoing certainty of the clinical benefit for immunocompromised patients against new SARS‐CoV‐2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsCOVID-19SARS-CoV-2Treatment OutcomeImmunocompromised HostHumansAntibodies, MonoclonalSpike Glycoprotein, CoronavirusBreakthrough Infections

Stichwörter der Autor:innen

COVID-19SARS-CoV-2efficacyimmunocompromisedtixagevimab/cilgavimab

Substanzen

Antibodies, Monoclonaltixagevimabspike protein, SARS-CoV-2Spike Glycoprotein, Coronaviruscilgavimab

Autor:innen und Institutionen

  • Oxford Medical School, University of Oxford, Oxford, UK.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • United Kingdom Health Security Agency (UKHSA), London, UK.
  • King's College Hospital and King's College, London, UK.
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Department of Oncology, University of Oxford, Oxford, UK.

ORCID-Profile: Rhea Suribhatla, Thomas Starkey, Antonio Pagliuca, Alex Richter, Lennard Y W Lee

Zitieren

APA

Suribhatla, R., Starkey, T., Ionescu, M. C., Pagliuca, A., Richter, A., & Lee, L. Y. W. (2023). Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18782

Vancouver

Suribhatla R, Starkey T, Ionescu MC, Pagliuca A, Richter A, Lee LYW. Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients. British Journal of Haematology. 2023. doi:10.1111/bjh.18782

BibTeX
@article{Suribhatla2023,
  author = {Suribhatla, Rhea and Starkey, Thomas and Ionescu, Maria C and Pagliuca, Antonio and Richter, Alex and Lee, Lennard Y W},
  title = {Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18782}
}
Kostenlos starten →